Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC trial in early peripheral spondyloarthritis
2019-004961-42Phase 3Active
- Sponsor
- Ghent University Hospital
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of golimumab, methotrexate and 5-aminosalicylic acid + sulphasalazine in peripheral spondyloarthritis (pSpA) (2 arms), sponsored by Ghent University Hospital. Started May 2020; status: active.
02
Drugs
golimumabmethotrexate5-aminosalicylic acid + sulphasalazine
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on 2019-004961-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004961-42.